CAR-T Cell Therapy for Severe Autoimmune Rheumatic Disease
Treatments studied
Part of Bones, joints & muscles, Brain & nervous system, Immune system & allergy, Skin clinical trials.
This trial tests a new type of immune cell therapy (CAR-T cells) designed to treat severe autoimmune rheumatic diseases like rheumatoid arthritis, lupus, or scleroderma that have not responded well to standard treatments. The therapy works by modifying your own immune cells to help control the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18–75 years old and in generally fair or better health (able to care for yourself or with minimal help)
- Diagnosed with a severe, treatment-resistant autoimmune rheumatic disease (rheumatoid arthritis, lupus, Sjögren's syndrome, scleroderma, or inflammatory muscle disease)
- Kidney function adequate enough for the treatment (creatinine clearance above 30 mL/min)
- No active serious infections, including hepatitis B or C, HIV, or recurring infections
- No history of cancer in the past 2 years, prior CAR-T or gene therapy, or previous organ/stem cell transplant
- Heart, liver, and lung function adequate; willing to use birth control for 12 months after treatment if able to become pregnant
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if a special immune cell therapy (CAR-T) can help people with certain autoimmune diseases like lupus, Sjogren's syndrome, scleroderma, myositis, vasculitis, or antiphospholipid syndrome that haven't improved with standard treatments. It is a very early phase study to check safety and effectiveness.
This trial tests a new CAR-T cell therapy (C-CAR168) for people with several autoimmune diseases that have not responded to standard treatments. It aims to see if this therapy can control the disease when other medicines have failed.
This trial tests a new type of immune therapy called CAR T-cells that target two markers on your B cells (CD19 and BCMA). It is for people with certain autoimmune diseases that have not improved or have come back after standard treatments. The goal is to see if this therapy can help control the disease.
This trial tests a new type of 'universal' CAR-T cell therapy (made from donor cells) combined with immune-suppressing drugs for people with severe autoimmune diseases that haven't responded to standard treatments. The goal is to see if this approach can control the immune system and reduce disease activity.
This study tests a new type of immune cell therapy (CAR-T cells) designed to treat severe autoimmune diseases like rheumatoid arthritis, lupus, dermatomyositis, and scleroderma that haven't responded well to standard treatments. The therapy works by modifying your own immune cells to target and eliminate the B cells that are causing your autoimmune disease.
This trial tests a new CAR-T cell therapy (a type of immune cell treatment) for people with certain autoimmune diseases, including lupus, scleroderma, and others. The goal is to see if the treatment can help control the disease.
Hear when a new Systemic Sclerosis (SSc) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.